You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR-TKI

Showing 1 - 25 of 2,146
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Nintedanib, gefitinib, erlotinib, afatinib
  • (no location specified)
Oct 2, 2023

IASLC Grading System as a Predictor for EGFR-TKI Therapy

Completed
  • Lung Cancer
  • IASLC grading system
  • Shanghai, Please Select, China
    Chaoqiang Deng
Nov 9, 2023

Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant

Completed
  • The Primary Study Metric is Progression-free Survival (PFS)
    • (no location specified)
    Jun 28, 2023

    NSCLC Trial in Singapore (Afatinib 40 MG)

    Not yet recruiting
    • NSCLC
    • Afatinib 40 MG
    • Singapore, Singapore
      National University Hospital
    Sep 25, 2023

    EGFR Mutant Advanced NSCLC Trial (BBT-207)

    Not yet recruiting
    • EGFR Mutant Advanced Non-Small Cell Lung Cancer
    • (no location specified)
    Jun 16, 2023

    NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

    Recruiting
    • NSCLC
    • EGFR Gene Mutation
    • neo-antigen vaccine
    • Nanjing, China
      The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
    Oct 19, 2023

    NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • HS-10241+ Almonertinib
    • Pemetrexed + Cisplatin /Carboplatin
    • (no location specified)
    Oct 29, 2023

    Dalpiciclib Combined With Third-generation EGFR-TKI in EGFR

    Not yet recruiting
    • Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
    • +6 more
      • (no location specified)
      Aug 9, 2022

      NSCLC Trial in Shanghai (IN10018, Furmonertinib)

      Recruiting
      • NSCLC
      • Shanghai, China
        Shanghai Pulmonary Hospital
      Aug 8, 2023

      A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

      Recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • +4 more
        • Guangzhou, Guangdong, China
          Cancer Center, Sun Yat-sen University
        Oct 25, 2022

        Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

        Recruiting
        • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
        • Topical Timolol
        • Hong Kong, Hong Kong
          Queen Mary Hospital
        Nov 14, 2023

        Brain Metastases, NSCLC Trial in Shanghai (EGFR-TK Inhibitor, Stereotactic radiotherapy)

        Recruiting
        • Brain Metastases
        • Non-small Cell Lung Cancer
        • EGFR-TK Inhibitor
        • Stereotactic radiotherapy
        • Shanghai, Shanghai, China
          Fudan University Shanghai Cancer Center
        Aug 27, 2023

        Bronchial Tumors Trial in Germany, Spain (EGF816, Trametinib)

        Recruiting
        • Bronchial Neoplasms
        • Cologne, Germany
        • +6 more
        Nov 2, 2022

        EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

        Recruiting
        • Non-small Cell Lung Cancer
          • Changsha, Hunan, China
            Yongchang Zhang
          Feb 28, 2022

          Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

          Recruiting
          • Non-Squamous Non-Small Cell Lung Cancer
          • Shanghai, Shanghai, China
            Shanghai Chest Hospital
          Sep 22, 2022

          NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

          Not yet recruiting
          • Non-small Cell Lung Cancer
          • (no location specified)
          May 23, 2023

          NSCLC Trial (PM8002, Placebo, Carboplatin)

          Not yet recruiting
          • NSCLC
          • (no location specified)
          Feb 23, 2023

          NSCLC Trial in Seoul (BBT-176, Cetuximab)

          Recruiting
          • NSCLC
          • Seongnam-si, Gyeonggi-do, Korea, Republic of
          • +3 more
          Jan 6, 2023

          Advanced Lung Adenocarcinoma Trial (TCM Formula, Placebo)

          Completed
          • Advanced Lung Adenocarcinoma
          • TCM Formula
          • Placebo
          • (no location specified)
          Jan 9, 2022

          NSCLC Trial in Chendu (Almonertinib)

          Recruiting
          • Non-small Cell Lung Cancer
          • Chendu, Sichuan, China
            West China Hospital，Sichuan University
          Dec 14, 2022

          NSCLC Trial (QLH11811)

          Not yet recruiting
          • Non-small Cell Lung Cancer
          • (no location specified)
          Sep 22, 2022

          Locally Advanced or Metastatic NSCLC Patients, Progressed From

          Active, not recruiting
          • Locally Advanced or Metastatic NSCLC
            • Beijing, China
            • +16 more
            Dec 16, 2022

            Advanced NSCLC Trial (VIC-1911, Osimertinib Mesylate Tablets)

            Not yet recruiting
            • Advanced Non-small Cell Lung Cancer
            • (no location specified)
            Aug 3, 2022

            PD-1 Blockade Plus Platinum-based Chemotherapy in EGFR Sensitive

            Completed
            • Non Small Cell Lung Cancer
              • Changsha, Hunan, China
                Hunan Cancer Hospital
              Mar 9, 2022

              Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)

              Recruiting
              • Non Small Cell Lung Cancer
              • Tianjin, Tianjin, China
                Tianjin Medical University Cancer Institute and Hospital
              Aug 18, 2022